P1456: EARLY SAFETY AND CLINICAL COURSE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MEASURABLE RESIDUAL DISEASE RECEIVING GTA002, AN OFF-THE-SHELF, EX VIVO-CULTURED ALLOGENEIC NK CELL PREPARATION
P1456：接受 GTA002（一种现成的体外培养同种异体 NK 细胞制剂）治疗的急性髓系白血病伴可测量残留病灶患者的早期安全性和临床病程
期刊:Deutsches Arzteblatt International
影响因子:7.1
doi:10.3238/arztebl.m2022.0205
Feurle, Gerhard E; Moos, Verena; Einsele, H; Moreau, P; Delforge, M; van de Donk, N W; Ghilotti, F; Diels, J; Elsada, A; Strulev, V; Pei, L; Kobos, R; Smit, J; Slavcev, M; Weisel, K; Mateos, M-V; Einsele, H; Moreau, P; De Stefano, V; Dytfeld, D; Angelucci, E; Benjamin, R; Goldschmidt, H; van de Donk, N W; Besemer, B; Scheid, C; Vij, R; ’. Groen-Damen, E I; Semerjian, M; Strulev, V; Schecter, J M; Roccia, T; Nesheiwat, T; Wapenaar, R; Weisel, K; Mateos, M-V; Heuser, M; Fiedler, W; Block, A; de Leeuw, D C; van de Loosdrecht, A; Astrid Tschan-Plessl, A; Passweg, J; Kloos, A; Schwarzer, A; Venturini, L; Duru, A D; Pinkernell, K; Ganser, A
